Autolus Therapeutics Plc (AUTL) Stock Price & Analysis

Autolus Therapeutics Plc (AUTL) fell 2.18% to USD 2.24 as of September 8, 2026 at 06:22 UTC, according to Nexqual real-time market data.

AUTL last closed at USD 2.24; the session ranged USD 2.22–2.3 on volume of 1,836,156 shares. Market capitalization is —, with a 52-week range of USD 1.18–2.58 (NMS). Source: Nexqual, September 8, 2026 at 06:22 UTC.

Key Statistics (as of September 8, 2026 at 06:22 UTC)

Technical Analysis (AUTL)

Nexqual's technical model rates AUTL "BUY" based on 5 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 06:22 UTC.

From Autolus Therapeutics Plc's Latest SEC 10-K Filing (filed 2026-03-27)

Key Strengths & Strategy (as disclosed to the SEC)

• CAR T Cell Production      We have developed our own proprietary viral vector and semi-automated cell manufacturing processes to engineer a patient's T cells with the CAR and other programming modules.
• We believe our scalable closed-system manufacturing process, along with our proprietary and modular T cell programming technologies, would be challenging and costly for potential competitors to replicate.
• Our T cell programming technologies allow us to tailor our therapies to address the specific disease we are targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to better recognize target cells and overcome fundamental disease defense mechanisms.
• We believe our commercial product and our clinical-stage product candidates and our approach to T cell programming have the potential to address these limitations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:22 UTC. This page is informational and not investment advice.